Nasus Pharma Ltd. (NSRX) Stock Analysis & Investment Frameworks
Nasus Pharma Ltd. (NSRX) stock analysis on Invetso. Review Nasus Pharma Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Nasus Pharma Ltd. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: IL
Nasus Pharma Ltd. Key Financial Metrics
- Market Cap: $27.39M
- Revenue: $N/A
- ROE: -158.83%
- ROIC: -96.46%
- Dividend Yield: N/A
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd. Investment Frameworks
Invetso analyzes Nasus Pharma Ltd. (NSRX) across the following frameworks:
- Nasus Pharma Ltd. 10Y Growth Potential
- Nasus Pharma Ltd. Scenario Analysis
- Nasus Pharma Ltd. Risks & Opportunities
- Nasus Pharma Ltd. Economic Moat
- Nasus Pharma Ltd. Business Model
- Nasus Pharma Ltd. Management
- Nasus Pharma Ltd. SWOT Analysis
- Nasus Pharma Ltd. Porter's 5 Forces
- Nasus Pharma Ltd. PESTLE Analysis
- Nasus Pharma Ltd. ESG Analysis